{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:16:36Z","timestamp":1782774996155,"version":"3.54.5"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"this study was supported by boehringer ingelheim international gmbh (bi)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s13318-021-00728-7","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T03:11:37Z","timestamp":1634613097000},"page":"81-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Drug\u2013Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease"],"prefix":"10.1007","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct03675581","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-9907","authenticated-orcid":false,"given":"Madelon C.","family":"Vonk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Guill\u00e9n-Del-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Avis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristell","family":"Marzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome R.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Wind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gahlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"728_CR1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1124\/jpet.117.244129","volume":"364","author":"F Hilberg","year":"2018","unstructured":"Hilberg F, Tontsch-Grunt U, Baum A, et al. Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases. J Pharmacol Exp Ther. 2018;364:494\u2013503.","journal-title":"J Pharmacol Exp Ther"},{"key":"728_CR2","doi-asserted-by":"crossref","unstructured":"Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54(3):1900161.","DOI":"10.1183\/13993003.00161-2019"},{"key":"728_CR3","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"728_CR4","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518\u201328.","journal-title":"N Engl J Med"},{"key":"728_CR5","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718\u201327.","journal-title":"N Engl J Med"},{"key":"728_CR6","unstructured":"Boehringer Ingelheim International GmbH. OFEV\u00ae (nintedanib) prescribing information. 2020. https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Ofev\/ofev.pdf. Accessed 30 Mar 2021."},{"key":"728_CR7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","volume":"58","author":"S Wind","year":"2019","unstructured":"Wind S, Schmid U, Freiwald M, et al. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet. 2019;58:1131\u201347.","journal-title":"Clin Pharmacokinet"},{"key":"728_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/00498254.2010.545452","volume":"41","author":"P Stopfer","year":"2011","unstructured":"Stopfer P, Rathgen K, Bischoff D, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011;41:297\u2013311.","journal-title":"Xenobiotica"},{"key":"728_CR9","doi-asserted-by":"crossref","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737\u201347.","DOI":"10.1002\/art.38098"},{"key":"728_CR10","unstructured":"Bayer plc. Microgynon\u00ae 30: summary of product characteristics. 2020."},{"key":"728_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0009-9236(99)70138-4","volume":"65","author":"P Barditch-Crovo","year":"1999","unstructured":"Barditch-Crovo P, Trapnell CB, Ette E, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther. 1999;65:428\u201338.","journal-title":"Clin Pharmacol Ther"},{"key":"728_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.contraception.2016.07.010","volume":"94","author":"EN Berry-Bibee","year":"2016","unstructured":"Berry-Bibee EN, Kim MJ, Tepper NK, et al. Co-administration of St. John\u2019s wort and hormonal contraceptives: a systematic review. Contraception. 2016;94:668\u201377.","journal-title":"Contraception"},{"key":"728_CR13","unstructured":"FDA Center for Drug Evaluation and Research. Nintedanib clinical pharmacology NDA review. 2014. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205832Orig1s000ClinPharmR.pdf. Accessed 30 Mar 2021."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00728-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-021-00728-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00728-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T05:07:16Z","timestamp":1641964036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-021-00728-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1007\/s13318-021-00728-7","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"28 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Boehringer Ingelheim International GmbH (BI).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MCV reports grants from BI, Ferrer and Janssen-Cilag; fees for serving as an advisor or review panel member for BI and Janssen-Cilag; and speaker fees from BI, Janssen-Cilag, Novartis, Roche. AG-D-C reports consultancy fees from BI and Janssen. MK reports grants from BI and Roche and consultancy fees from BI, Galapagos, Roche. MA, KM, SRM, SW and MG are employees of BI.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Researchers may request access to de-identified participant clinical study data with documentation describing the structure and content of the datasets. Upon approval, and governed by a Data Sharing Agreement, data would be shared in a secured data-access system for a period of 1 year, which may be extended upon request. Researchers should use the link  to request access to study data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"MA, KM, SRM, SW and MG were involved in the design of the study. MCV, AG-D-C and MK were involved in data acquisition. SRM and KM were involved in data analysis. All authors were involved in the interpretation of the data and in the writing and critical review of the manuscript and have approved the final version.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"The clinical protocol was approved by an independent ethics committee or institutional review board at each participating centre.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before study entry.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}